Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc.

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Today, 2/3/2026, According to Top Analysts

Insiders have been trading these 5 stocks: (($AEHR)), (($FAST)), (($RF)), (($ABEO)) and (($TSHA)). Here is a breakdown of their recent trades and t...

Aehr, Fastenal, Regions, Abeona, Taysha: Insider Firestorm

Insiders have been trading these 5 stocks: (($PLAY)), (($AEO)), (($CABA)), (($ABEO)) and (($ONCY)). Here is a breakdown of their recent trades and ...

Dave & Buster’s, American Eagle, Cabaletta, Abeona, Oncolytics Insider Shock

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ANI Pharmaceuticals (ANIP – Research Report), Abeona...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABEO	$5.27	+1.93%	963.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABEO	$5.27	+1.9%	963.27K
3
4
5
6

ABEO

ABEO

Dividend Overview

Get Abeona Therapeutics Inc. Data in Excel

Get Abeona Therapeutics Inc. Data in Excel